Company
Camp4
Pioneering a new class of RNA medicines to increase targeted gene expression
- Business model
- B2B
- Legal name
- CAMP4 Therapeutics Corporation
Claim, correct or request removal
Record updated 28 September 2026
About
Camp4 (CAMP) is a clinical-stage biotechnology company with core thesis to restore healthy gene expression in diseased cells by programmable modulation of a new class of RNA.
Funding snapshot
- Total raised
- $180MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $100M2022-06-03
Funding rounds
- Round, 2022
- $100M2022-06-03, SEC form D sold, 16 investors
- Round, 2021
- $45M2021-03-05, SEC form D sold, 7 investors
- Round, 2018
- $34.1M2018-04-20, SEC form D sold, 6 investors
Products
- Web
- RAP Platform®
Loading relationship preview